Solid Biosciences Climbs After Multiple Trial Updates

Shares of Solid Biosciences rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug. The ...

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Ventricular Tachycardia Market to Hit $22.28 Billion by 2032, at a CAGR of 5.3%, says Coherent Market Insights

The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...
The Cardiology Advisor

Mavacamten Significantly Improves Symptomatic oHCM in Adolescent Population

SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.